Comparing Amarillo Biosciences (OTCMKTS:AMAR) & AstroNova (NASDAQ:ALOT)

AstroNova (NASDAQ:ALOT) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Earnings & Valuation

This table compares AstroNova and Amarillo Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstroNova	$150.51 million	1.51	-$2.38 million	($0.18)	-160.67
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A

Amarillo Biosciences has lower revenue, but higher earnings than AstroNova.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AstroNova and Amarillo Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstroNova	1	0	0	0	1.00
Amarillo Biosciences	0	0	0	0	0.00

Given Amarillo Biosciences’ higher possible upside, analysts clearly believe Amarillo Biosciences is more favorable than AstroNova.

Institutional and Insider Ownership

43.0% of AstroNova shares are owned by institutional investors. 12.6% of AstroNova shares are owned by insiders. Comparatively, 34.4% of Amarillo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

AstroNova has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Profitability

This table compares AstroNova and Amarillo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AstroNova	-0.88%	2.94%	1.61%
Amarillo Biosciences	-41,453.98%	N/A	-574.29%

Summary

AstroNova beats Amarillo Biosciences on 7 of the 10 factors compared between the two stocks.

About AstroNova

AstroNova, Inc. designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Europe, Asia, Canada, Central and South America, and internationally. The company operates in two segments, Product Identification (PI) and Test & Measurement (T&M). The PI segment offers tabletop and production-ready digital color label printers, and OEM printing systems under the QuickLabel brand; digital color label mini-presses and inline printing systems under the TrojanLabel brand; and label materials, tags material, inks, toners, and thermal transfer ribbions under the GetLabels brand. This segment also develops and licenses various specialized software programs to design and manage labels and print images; and provides training and support. This segment serves chemicals, cosmetics, food and beverage, medical products, nutraceuticals, pharmaceuticals, and other industries; and brand owners, label converters, commercial printers, and packaging manufacturers. The T&M segment offers airborne printing solutions, such as ToughWriter used to print hard copies of navigation maps, arrival and departure information, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data; ToughSwitch, an ethernet switches used to connect multiple computers or Ethernet devices; TMX data acquisition systems; Daxus DXS-100 distributed data acquisition platform; SmartCorder DDX100 portable data acquisition systems for facility and field testing; and Everest EV-5000, a digital strip chart recording system used primarily in aerospace and defense. This segment serves aerospace and aerospace and defense, automotive, commercial airline, energy, manufacturing, and transportation industries. The company was formerly known as Astro-Med, Inc. and changed its name to AstroNova, Inc. in May 2016. AstroNova, Inc. was incorporated in 1969 and is headquartered in West Warwick, Rhode Island.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.